Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune‐mediated inflammatory diseases: A longitudinal population‐based analysis using claims data-Reference-Cited by-同舟云学术

Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune‐mediated inflammatory diseases: A longitudinal population‐based analysis using claims data

Published:2020-12 Issue:4 Volume:3 Page:
ISSN:2398-8835
Container-title:Health Science Reports
language:en
Short-container-title:Health Sci Rep

Author:

Iba Arisa¹^ORCID,Tomio Jun¹,Yamana Hayato²,Sugiyama Takehiro³⁴⁵^ORCID,Yoshiyama Takashi⁶,Kobayashi Yasuki¹

Affiliation:

1. Department of Public Health Graduate School of Medicine, The University of Tokyo Tokyo Japan

2. Department of Health Services Research Graduate School of Medicine, The University of Tokyo Tokyo Japan

3. Diabetes and Metabolism Information Center Research Institute, National Center for Global Health and Medicine Tokyo Japan

4. Institute for Global Health Policy Research, Bureau of International Health Cooperation National Center for Global Health and Medicine Tokyo Japan

5. Department of Health Services Research, Faculty of Medicine University of Tsukuba Ibaraki Japan

6. Research Institute of Tuberculosis Japan Anti Tuberculosis Association Tokyo Japan

Funder

NEC Corporation

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hsr2.216

Reference48 articles.

1. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability

2. Abatacept treatment for rheumatoid arthritis

3. Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor

4. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

5. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge and Attitudes About Screening and Preventive Treatment of Latent Tuberculosis Infection Among Patients with Rheumatic Diseases in Beijing, China;Infection and Drug Resistance;2024-08

2. Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018–2021;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

3. Incidence of New-Onset Inflammatory Bowel Disease, Oral and Gastrointestinal Candidiasis, Herpes Zoster, Pulmonary Tuberculosis, and Major Cardiovascular Events in Patients with Moderate-to-Severe Psoriasis Exposed to Biologics;Journal of Clinical Medicine;2023-12-13

4. Infectious issues of therapeutic monoclonal antibodies in multiple sclerosis and neuromyelitis optica spectrum disorders;Clinical and Experimental Neuroimmunology;2022-07-27

5. Hospitalizations for Ambulatory Care Sensitive Conditions in a Large City of Japan: a Descriptive Analysis Using Claims Data;Journal of General Internal Medicine;2022-07-12